Tevogen Bio Holdings Inc (TVGN)

$7.55 +0.54 (7.70%)
Market Cap 29.19M
Revenue (ttm) 0.00
Net Income (ttm) -26.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.53
Volume 11,700
Avg Vol 33,545
Day's Range N/A - N/A
Shares Out 4.16M
Stochastic %K 50%
Beta -0.32
Analysts Hold
Price Target $100.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6434
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #210, Warren, United States
NGCS
NGCS Apr. 25 at 11:17 PM
$TVGN 4. Value Perspective (The "Master Move"): - The thesis holds that management will force the closing of all three agreements in a single, high-impact announcement. - This aims to trigger a Short Squeeze, catapulting the stock from current levels (~$7.55) toward $35-$40. - At that price, the company can perform a controlled, strategic dilution to secure long-term funding while easily exceeding Nasdaq requirements. - Getting 102 usd per share would not be so far from this point. Best regards.
0 · Reply
NGCS
NGCS Apr. 25 at 11:16 PM
$TVGN 3. Rationale: Economic, Professional, and Personal Necessity Economic: - Tevogen needs real revenue to transition from a "speculative" biotech to a commercial pharma. - Closing these deals triggers warrants (~$11.50-$12 strike), injecting cash without taking on debt. - Professional: The prestige of Dr. Ryan Saadi and his team depends on executing this "Total Transformation Operation." They need a "Big Bang" news event to attract institutional funds. - Personal/Cultural (Apozeal & Tevogen): The New Jersey-based connection between the owners (Indian-American business community) fosters trust and simplifies the due diligence process. It is a sober pharma project (Made in USA) that adds significant political and strategic value.
0 · Reply
NGCS
NGCS Apr. 25 at 11:14 PM
$TVGN 2. Estimated Timelines (Key Catalysts): Critical Window: From today to June 2, 2026: - Milestone 1 (May): Quarterly earnings report. Management is expected to move from Letters of Intent (LOI) to official company names and definitive closing dates. - Milestone 2 (June): The market's "patience limit," marking 3 months since the LOIs were signed. - Milestone 3 (October): Nasdaq deadline to regain a minimum $50M market capitalization.
0 · Reply
NGCS
NGCS Apr. 25 at 11:11 PM
$TVGN Executive Summary: Tevogen Bio (TVGN) Strategic Roadmap to 102 usd/sh as fintel and other webs (My own DD 26th april 2026, NFA): 1. Contract Status & Probability of Success - The CRO (Clinical Services): (85% Probability). This is the essential infrastructure. It would bring in $20M in annual revenue and massive operational savings by bringing clinical trials in-house. - Clinicus (Sciometrix): (75% Probability). This is the technological data foundation. It is vital to validate the Artificial Intelligence narrative for institutional investors. - Apozeal Pharmaceuticals: (70-75% Probability). This is the valuation "rocket." It provides 11 FDA-approved products and domestic manufacturing capacity.
0 · Reply
NGCS
NGCS Apr. 24 at 10:50 PM
$TVGN IMO it is a question of time that this stock will do same path as $DRUG (DRUG still zero revenue in 2026, and TVGN maybe 50-100 million this year 2026 if Apozeal and Clinicus contracts signed from LoI). DRUG went up from $1,10 to $40 in 2 days (oct 2024) with no revenue, and in january 2026 became $120 in also 2 days (today is $89). TVGN would have 50-100 million revenue in 2026. DRUG market cap is $900 Million and 12 million shares, and TVGN market cap is only $31 million and 4,1 million shares (30 times less than DRUG). I sold DRUG shares in oct 2024 (you can check up my posts in oct 2024) and I am sure that TVGN will be the same way in 4 - 14 months (from 7 usd to 100 usd, IMO). NFA, please do your own DD. Best regards!
1 · Reply
entoen
entoen Apr. 24 at 4:15 PM
$TVGN hmm, there is so much potential in this company
0 · Reply
Lifefinder
Lifefinder Apr. 24 at 3:00 PM
$TVGN freaky Friday’s … this will blow up soon !!!
0 · Reply
Reminderz
Reminderz Apr. 23 at 8:12 PM
$TVGN $GSIW $TR $AEHL game
0 · Reply
dcme010711
dcme010711 Apr. 21 at 2:16 PM
$TVGN guessing a squeeze, not much to borrow and cost to borrow rates have been increasing slowly over last month or so
1 · Reply
topstockalerts
topstockalerts Apr. 21 at 12:24 PM
Pre Market Top Gainers PT2 $XRTX $TVGN $BYND $FULT $UNHG
0 · Reply
Latest News on TVGN
Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Mar 26, 2026, 12:45 PM EDT - 4 weeks ago

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 25, 2026, 2:20 PM EDT - 4 weeks ago

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Mar 18, 2026, 12:22 PM EDT - 5 weeks ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Mar 13, 2026, 2:45 PM EDT - 6 weeks ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 13, 2026, 12:30 PM EDT - 6 weeks ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Mar 11, 2026, 3:15 PM EDT - 6 weeks ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Mar 9, 2026, 7:45 AM EDT - 6 weeks ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Letter to Shareholders from CEO Dr. Ryan Saadi

Mar 6, 2026, 3:40 PM EST - 7 weeks ago

Letter to Shareholders from CEO Dr. Ryan Saadi

Tevogen Bio Explores Buyout To Boost Generics Platform

Mar 6, 2026, 12:42 PM EST - 7 weeks ago

Tevogen Bio Explores Buyout To Boost Generics Platform

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Mar 5, 2026, 2:50 PM EST - 7 weeks ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

Tevogen Announces Reverse Stock Split

Mar 4, 2026, 8:00 AM EST - 7 weeks ago

Tevogen Announces Reverse Stock Split

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 27, 2026, 2:20 PM EST - 2 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 4:22 PM EST - 2 months ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Feb 26, 2026, 9:20 AM EST - 2 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 30, 2026, 3:00 PM EST - 3 months ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Jan 29, 2026, 2:45 PM EST - 3 months ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Jan 12, 2026, 9:00 AM EST - 3 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 22, 2025, 12:40 PM EST - 4 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 19, 2025, 11:10 AM EST - 4 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 11, 2025, 3:15 PM EST - 4 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 9, 2025, 2:20 PM EST - 4 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Dec 8, 2025, 2:50 PM EST - 4 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Nov 14, 2025, 2:32 PM EST - 5 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 5, 2025, 3:20 PM EST - 6 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Nov 3, 2025, 2:45 PM EST - 6 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 29, 2025, 12:35 PM EDT - 6 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Oct 15, 2025, 3:50 PM EDT - 6 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 25, 2025, 8:30 AM EDT - 7 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 23, 2025, 8:30 AM EDT - 7 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 19, 2025, 3:40 PM EDT - 7 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10, 2025, 11:59 AM EDT - 8 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 9, 2025, 3:15 PM EDT - 8 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 8, 2025, 9:27 AM EDT - 8 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 4, 2025, 3:48 PM EDT - 8 months ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Sep 3, 2025, 4:15 PM EDT - 8 months ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 27, 2025, 3:20 PM EDT - 8 months ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 26, 2025, 2:50 PM EDT - 8 months ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 25, 2025, 3:10 PM EDT - 8 months ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 22, 2025, 3:25 PM EDT - 8 months ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 3:40 PM EDT - 8 months ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 19, 2025, 12:10 PM EDT - 8 months ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:50 PM EDT - 8 months ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 18, 2025, 5:15 PM EDT - 8 months ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 14, 2025, 3:55 PM EDT - 9 months ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 13, 2025, 3:53 PM EDT - 9 months ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 3:45 PM EDT - 9 months ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Aug 11, 2025, 1:24 PM EDT - 9 months ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Aug 11, 2025, 11:58 AM EDT - 9 months ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 11, 2025, 9:28 AM EDT - 9 months ago

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 8, 2025, 11:37 AM EDT - 9 months ago

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

NGCS
NGCS Apr. 25 at 11:17 PM
$TVGN 4. Value Perspective (The "Master Move"): - The thesis holds that management will force the closing of all three agreements in a single, high-impact announcement. - This aims to trigger a Short Squeeze, catapulting the stock from current levels (~$7.55) toward $35-$40. - At that price, the company can perform a controlled, strategic dilution to secure long-term funding while easily exceeding Nasdaq requirements. - Getting 102 usd per share would not be so far from this point. Best regards.
0 · Reply
NGCS
NGCS Apr. 25 at 11:16 PM
$TVGN 3. Rationale: Economic, Professional, and Personal Necessity Economic: - Tevogen needs real revenue to transition from a "speculative" biotech to a commercial pharma. - Closing these deals triggers warrants (~$11.50-$12 strike), injecting cash without taking on debt. - Professional: The prestige of Dr. Ryan Saadi and his team depends on executing this "Total Transformation Operation." They need a "Big Bang" news event to attract institutional funds. - Personal/Cultural (Apozeal & Tevogen): The New Jersey-based connection between the owners (Indian-American business community) fosters trust and simplifies the due diligence process. It is a sober pharma project (Made in USA) that adds significant political and strategic value.
0 · Reply
NGCS
NGCS Apr. 25 at 11:14 PM
$TVGN 2. Estimated Timelines (Key Catalysts): Critical Window: From today to June 2, 2026: - Milestone 1 (May): Quarterly earnings report. Management is expected to move from Letters of Intent (LOI) to official company names and definitive closing dates. - Milestone 2 (June): The market's "patience limit," marking 3 months since the LOIs were signed. - Milestone 3 (October): Nasdaq deadline to regain a minimum $50M market capitalization.
0 · Reply
NGCS
NGCS Apr. 25 at 11:11 PM
$TVGN Executive Summary: Tevogen Bio (TVGN) Strategic Roadmap to 102 usd/sh as fintel and other webs (My own DD 26th april 2026, NFA): 1. Contract Status & Probability of Success - The CRO (Clinical Services): (85% Probability). This is the essential infrastructure. It would bring in $20M in annual revenue and massive operational savings by bringing clinical trials in-house. - Clinicus (Sciometrix): (75% Probability). This is the technological data foundation. It is vital to validate the Artificial Intelligence narrative for institutional investors. - Apozeal Pharmaceuticals: (70-75% Probability). This is the valuation "rocket." It provides 11 FDA-approved products and domestic manufacturing capacity.
0 · Reply
NGCS
NGCS Apr. 24 at 10:50 PM
$TVGN IMO it is a question of time that this stock will do same path as $DRUG (DRUG still zero revenue in 2026, and TVGN maybe 50-100 million this year 2026 if Apozeal and Clinicus contracts signed from LoI). DRUG went up from $1,10 to $40 in 2 days (oct 2024) with no revenue, and in january 2026 became $120 in also 2 days (today is $89). TVGN would have 50-100 million revenue in 2026. DRUG market cap is $900 Million and 12 million shares, and TVGN market cap is only $31 million and 4,1 million shares (30 times less than DRUG). I sold DRUG shares in oct 2024 (you can check up my posts in oct 2024) and I am sure that TVGN will be the same way in 4 - 14 months (from 7 usd to 100 usd, IMO). NFA, please do your own DD. Best regards!
1 · Reply
entoen
entoen Apr. 24 at 4:15 PM
$TVGN hmm, there is so much potential in this company
0 · Reply
Lifefinder
Lifefinder Apr. 24 at 3:00 PM
$TVGN freaky Friday’s … this will blow up soon !!!
0 · Reply
Reminderz
Reminderz Apr. 23 at 8:12 PM
$TVGN $GSIW $TR $AEHL game
0 · Reply
dcme010711
dcme010711 Apr. 21 at 2:16 PM
$TVGN guessing a squeeze, not much to borrow and cost to borrow rates have been increasing slowly over last month or so
1 · Reply
topstockalerts
topstockalerts Apr. 21 at 12:24 PM
Pre Market Top Gainers PT2 $XRTX $TVGN $BYND $FULT $UNHG
0 · Reply
topstockalerts
topstockalerts Apr. 21 at 11:28 AM
Pre Market Top Gainers PT2 $XRTX $TVGN $BYND $FULT $UNHG
0 · Reply
dcme010711
dcme010711 Apr. 21 at 1:42 AM
$TVGN wow, miss any news or this just a squeeze
1 · Reply
topstockalerts
topstockalerts Apr. 21 at 1:26 AM
After Hours Top Gainers PT2 $CTNT $TVGN $TOMZ $SLNH $AVEX
1 · Reply
BEATWALLSTREET
BEATWALLSTREET Apr. 21 at 1:22 AM
$TVGN Beat told you
0 · Reply
SpaceRunners
SpaceRunners Apr. 20 at 11:01 PM
$TVGN $CADL $COEP $QBTS :::
2 · Reply
thegreatone24
thegreatone24 Apr. 20 at 6:13 PM
$TVGN Strange that the warrants $TVGNW is down 5%
5 · Reply
Somerandomnoname
Somerandomnoname Apr. 20 at 5:24 PM
$TVGN :)
0 · Reply
Goingup10
Goingup10 Apr. 20 at 1:00 PM
$TVGN Thus will be $15 very soon and motor from there. Its way oversold on all metrics and one piece of good news will see this get back to a $100M market cap - currently only $28M.
1 · Reply
NGCS
NGCS Apr. 17 at 8:46 PM
$TVGN you have been aiming people to short this stock from 3rd dec, and now you say people not to buy this stock? Are you kidding us? You should cover your shorting instead of crying here. NFA.
2 · Reply
NGCS
NGCS Apr. 17 at 8:40 PM
$TVGN what about your shorting this? Try to cover as soon as posible, before K-8 comes out. NFA, only my DD.
0 · Reply
Chamelneon
Chamelneon Apr. 17 at 7:41 PM
$TVGN if you are new to this stock don’t be fooled. They did a 50 for 1 reverse split so the actual value of this right now for a lot of people is 14 cents.
2 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:40 AM
$TVGN hmm
0 · Reply